Literature DB >> 759879

Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis.

O Epstein, D De Villiers, S Jain, B J Potter, H C Thomas, S Sherlock.   

Abstract

Penicillamine has an effect on immune complexes and immunoglobulins both in vivo and in vitro. We therefore studied the effect of penicillamine on immune complexes and immunoglobulins in primary biliary cirrhosis. Twenty-eight patients were randomly allocated into a treatment group receiving 600 to 900 mg of penicillamine, or a control group, and followed for a maximum of 24 months. After 12 and 24 months, serum immune complexes had fallen significantly in treated patients as compared to controls (P less than 0.05, P less than 0.01). Treatment reduced IgA, IgG and IgM concentrations, with IgM being significantly different from controls at six, 12 and 24 months (P less than 0.01). Over 24 months, serum aspartate transaminase levels fell in treated patients but rose in controls (P less than 0.01). Bilirubin concentrations increased at a slower rate in treated patients. Penicillamine may favorably influence the course of primary biliary cirrhosis by its immunologic action in addition to its copper-chelating action.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 759879     DOI: 10.1056/NEJM197902083000602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  Suppressor cell activity in primary biliary cirrhosis.

Authors:  R K Zetterman; J A Woltjen
Journal:  Dig Dis Sci       Date:  1980-02       Impact factor: 3.199

Review 2.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

3.  D-penicillamine in the therapy of Indian childhood cirrhosis.

Authors:  S Bhave; A Pandit
Journal:  Indian J Pediatr       Date:  1987 Jul-Aug       Impact factor: 1.967

4.  Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis.

Authors:  J Neuberger; E Christensen; B Portmann; J Caballeria; J Rodes; L Ranek; N Tygstrup; R Williams
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

5.  D-penicillamine for primary biliary cirrhosis.

Authors:  O F James
Journal:  Gut       Date:  1985-02       Impact factor: 23.059

6.  Enzymes of collagen synthesis and type III procollagen aminopropeptide in the evaluation of D-penicillamine and medroxyprogesterone treatments of primary biliary cirrhosis.

Authors:  E R Savolainen; T A Miettinen; P Pikkarainen; M P Salaspuro; K I Kivirikko
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

Review 7.  Pathogenic mechanisms in primary biliary cirrhosis.

Authors:  H C Thomas; O Epstein
Journal:  Springer Semin Immunopathol       Date:  1980-12

Review 8.  Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases.

Authors:  I A Jaffe
Journal:  Springer Semin Immunopathol       Date:  1981

9.  Results of portal decompression in patients with primary biliary cirrhosis.

Authors:  R Spinsi; G Smith-Laing; O Epstein; S Sherlock
Journal:  Gut       Date:  1981-05       Impact factor: 23.059

10.  Complement activation in chronic liver disease.

Authors:  L E Munoz; D De Villiers; D Markham; K Whaley; H C Thomas
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.